2015尿路感染诊断与治疗中国专家共识

2015-12-16 编辑 淡然 尿路感染诊断与治疗中国专家共识(2015

导 语:.临床中制定尿路感染的治疗方案应遵循《抗菌药物临床应用指导原则》。抗菌治疗方案不仅包括抗菌药物的选用品种、剂量、给药次数、给药途径、疗程等,还需要综合考虑病原菌、感染部位、感染程度和患者的生理、病理情况。 品种选择 抗菌药物品种的选用应根据病原菌种类及病原菌对抗菌药物的敏感性,即细菌药物敏感试验的结果而定。对临床诊断为尿路感染的患者应在开始抗菌治疗前,及时留取合格尿标本

导 语:.临床中制定尿路感染的治疗方案应遵循《抗菌药物临床应用指导原则》。抗菌治疗方案不仅包括抗菌药物的选用品种、剂量、给药次数、给药途径、疗程等,还需要综合考虑病原菌、感染部位、感染程度和患者的生理、病理情况。

品种选择

抗菌药物品种的选用应根据病原菌种类及病原菌对抗菌药物的敏感性,即细菌药物敏感试验的结果而定。对临床诊断为尿路感染的患者应在开始抗菌治疗前,及时留取合格尿标本、怀疑存在血流感染时应留取血标本,并送病原学检测,以尽早明确病原菌和药敏试验结果,并据此调整抗菌药物的治疗方案。

对于临床诊断为细菌性感染的患者,在未获知病原菌药敏试验结果前,可根据患者的感染部位(上尿路还是下尿路)、发病情况、发病场所(医院感染还是社区感染)、既往抗菌药物用药史及其治疗反应等推测可能的病原体,并结合当地细菌耐药性监测数据,先给予抗菌药物经验性治疗。待获知病原学检测及药敏试验结果后,结合先前的治疗反应调整用药方案。

此外,应根据不同药物的代谢动力学特点并结合患者感染部位选择抗菌药物。左氧氟沙星和β-内酰胺类抗菌药物的血药浓度和尿药浓度均较高,既可用于治疗下尿路感染,又可用于治疗上尿路感染。

给药剂量

按各种抗菌药物的治疗剂量范围给药。治疗上尿路感染,尤其是严重感染时,抗菌药物剂量宜较大(治疗剂量范围高限);而治疗单纯性下尿路感染时,由于多数药物尿药浓度远高于血药浓度,则可应用较小剂量(治疗剂量范围低限)。同时,要根据患者肝肾功能情况调整给药剂量。

给药途径

对于下尿路感染的患者,应予口服药物治疗。选取口服吸收良好的抗菌药物品种,不必采用静脉或肌内注射给药。仅在下列情况下可先予以注射给药:

1)不能口服或不能耐受口服给药的患者(如吞咽困难者);

2)患者存在可能明显影响口服药物吸收的情况(如呕吐、严重腹泻、胃肠道病变或肠道吸收功能障碍等);

3)所选药物有合适抗菌谱,但无口服剂型;

4)患者对治疗的依从性差。

对于上尿路感染,初始治疗多选用静脉用药,病情稳定后可酌情改为口服药物。
给药次数
为保证药物在体内能发挥最大药效,杀灭感染灶病原菌,应根据药代动力学/药效动力学原理、患者病情严重程度和肝肾功能状况等决定给药次数。

抗菌药物分为时间依赖性抗菌药物和浓度依赖性抗菌药物。

时间依赖性抗菌药物的浓度达到一定程度后再增加浓度,抗菌作用无明显增强,其抗菌效果与药物浓度高于最低抑菌浓度(T>MIC)的时间相关,即感染部位游离药物浓度高于MIC时间越长,抗菌效果越好。

浓度依赖性抗菌药物如喹诺酮类和氨基糖苷类,药物浓度越高抗菌效果越好,因此这类药物大多一日一次给药。

疗程

抗菌药物使用疗程因感染位置不同而异,对于急性单纯性下尿路感染,疗程基本少于7天。上尿路感染,如急性肾盂肾炎,疗程一般为2周。对于反复发作尿路感染,可根据情况进行长期抑菌治疗。

华医网编辑整理,编辑:淡然

来源:尿路感染诊断与治疗中国专家共识(2015版)——尿路感染抗菌药物选择策略

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1719016, encodeId=f1351e190161f, content=<a href='/topic/show?id=e32e915e89c' target=_blank style='color:#2F92EE;'>#诊断与治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91578, encryptionId=e32e915e89c, topicName=诊断与治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85a832689492, createdName=木头人524, createdTime=Thu Sep 08 23:21:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844469, encodeId=ee161844469fc, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Mon May 02 08:21:00 CST 2016, time=2016-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741355, encodeId=888d1e413553b, content=<a href='/topic/show?id=c2c621665c4' target=_blank style='color:#2F92EE;'>#中国专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21665, encryptionId=c2c621665c4, topicName=中国专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jul 29 22:21:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48414, encodeId=9c5848414cb, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:00:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47857, encodeId=cb004e8579d, content=具体情况具体对待,不宜一刀切。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLAibgOibuZnfdFE64hJHibbD6WwEgyaXx7DtibMOSicJ6JZoLEAIdAdkhDmHWO7P7OXg2tkTicZy9libryicw/0, createdBy=aa991670466, createdName=sword20000, createdTime=Sat Dec 26 07:23:00 CST 2015, time=2015-12-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1719016, encodeId=f1351e190161f, content=<a href='/topic/show?id=e32e915e89c' target=_blank style='color:#2F92EE;'>#诊断与治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91578, encryptionId=e32e915e89c, topicName=诊断与治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85a832689492, createdName=木头人524, createdTime=Thu Sep 08 23:21:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844469, encodeId=ee161844469fc, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Mon May 02 08:21:00 CST 2016, time=2016-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741355, encodeId=888d1e413553b, content=<a href='/topic/show?id=c2c621665c4' target=_blank style='color:#2F92EE;'>#中国专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21665, encryptionId=c2c621665c4, topicName=中国专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jul 29 22:21:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48414, encodeId=9c5848414cb, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:00:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47857, encodeId=cb004e8579d, content=具体情况具体对待,不宜一刀切。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLAibgOibuZnfdFE64hJHibbD6WwEgyaXx7DtibMOSicJ6JZoLEAIdAdkhDmHWO7P7OXg2tkTicZy9libryicw/0, createdBy=aa991670466, createdName=sword20000, createdTime=Sat Dec 26 07:23:00 CST 2015, time=2015-12-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1719016, encodeId=f1351e190161f, content=<a href='/topic/show?id=e32e915e89c' target=_blank style='color:#2F92EE;'>#诊断与治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91578, encryptionId=e32e915e89c, topicName=诊断与治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85a832689492, createdName=木头人524, createdTime=Thu Sep 08 23:21:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844469, encodeId=ee161844469fc, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Mon May 02 08:21:00 CST 2016, time=2016-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741355, encodeId=888d1e413553b, content=<a href='/topic/show?id=c2c621665c4' target=_blank style='color:#2F92EE;'>#中国专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21665, encryptionId=c2c621665c4, topicName=中国专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jul 29 22:21:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48414, encodeId=9c5848414cb, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:00:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47857, encodeId=cb004e8579d, content=具体情况具体对待,不宜一刀切。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLAibgOibuZnfdFE64hJHibbD6WwEgyaXx7DtibMOSicJ6JZoLEAIdAdkhDmHWO7P7OXg2tkTicZy9libryicw/0, createdBy=aa991670466, createdName=sword20000, createdTime=Sat Dec 26 07:23:00 CST 2015, time=2015-12-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1719016, encodeId=f1351e190161f, content=<a href='/topic/show?id=e32e915e89c' target=_blank style='color:#2F92EE;'>#诊断与治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91578, encryptionId=e32e915e89c, topicName=诊断与治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85a832689492, createdName=木头人524, createdTime=Thu Sep 08 23:21:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844469, encodeId=ee161844469fc, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Mon May 02 08:21:00 CST 2016, time=2016-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741355, encodeId=888d1e413553b, content=<a href='/topic/show?id=c2c621665c4' target=_blank style='color:#2F92EE;'>#中国专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21665, encryptionId=c2c621665c4, topicName=中国专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jul 29 22:21:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48414, encodeId=9c5848414cb, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:00:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47857, encodeId=cb004e8579d, content=具体情况具体对待,不宜一刀切。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLAibgOibuZnfdFE64hJHibbD6WwEgyaXx7DtibMOSicJ6JZoLEAIdAdkhDmHWO7P7OXg2tkTicZy9libryicw/0, createdBy=aa991670466, createdName=sword20000, createdTime=Sat Dec 26 07:23:00 CST 2015, time=2015-12-26, status=1, ipAttribution=)]
    2015-12-26 hixiaoluo

    好文章,值得看。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1719016, encodeId=f1351e190161f, content=<a href='/topic/show?id=e32e915e89c' target=_blank style='color:#2F92EE;'>#诊断与治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91578, encryptionId=e32e915e89c, topicName=诊断与治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85a832689492, createdName=木头人524, createdTime=Thu Sep 08 23:21:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844469, encodeId=ee161844469fc, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Mon May 02 08:21:00 CST 2016, time=2016-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741355, encodeId=888d1e413553b, content=<a href='/topic/show?id=c2c621665c4' target=_blank style='color:#2F92EE;'>#中国专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21665, encryptionId=c2c621665c4, topicName=中国专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jul 29 22:21:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48414, encodeId=9c5848414cb, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:00:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47857, encodeId=cb004e8579d, content=具体情况具体对待,不宜一刀切。, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLAibgOibuZnfdFE64hJHibbD6WwEgyaXx7DtibMOSicJ6JZoLEAIdAdkhDmHWO7P7OXg2tkTicZy9libryicw/0, createdBy=aa991670466, createdName=sword20000, createdTime=Sat Dec 26 07:23:00 CST 2015, time=2015-12-26, status=1, ipAttribution=)]
    2015-12-26 sword20000

    具体情况具体对待,不宜一刀切。

    0

相关资讯

AJOG:蔓越莓对抗尿路感染

蔓越莓含有丰富的维他命A﹑维他命C﹑维他命E﹑初花色素﹑磷﹑儿茶素, Vaccinin 等,具有非常好的抗氧化、抗菌功能。近年来的研究发现其是对付尿路感染的最佳武器之一。近期Foxman B等人进行了一项随机、双盲、安慰剂对照实验,以探究蔓越莓在行了导尿术的妇科手术病人中,预防术后尿路感染(UTI)的效能。有研究报道,妇科手术时插入导尿管,术后拔除尿管后,尿路感染(UTI)风险还是很高,波动在10

AJOG:尿路感染增加子痫前期风险

经过数十年的研究,现在对子痫前期孕妇体内生物标志物的识别有了很大的进展,不过子痫前期的的发病机制仍然是难以捉摸的。目前认为异常的胎盘形成和全身炎症系统的变化导致了子痫前期的病理生理变化。那么是不是会导致炎症反应的情况如感染等,都会通过机体的炎症反应而增加子痫前期发生风险?而孕期常见的感染有尿路感染,那么尿路感染会不会是导致孕妇子痫前期发病风险增加的因素?先前也有研究证实了两者间的关系,不过大多数都

FDA警告:糖尿病治疗新秀“SGLT2抑制剂”导致酮症酸中毒风险

近年来,钠-葡萄糖2型转运体(SGLT2)作为一个治疗糖尿病的新靶点受到广泛关注。SGLT2是一类特异性分布在肾脏近曲小管S1段的葡萄糖转运体,其生理功能是负责约90%葡萄糖的重吸收。SGLT2抑制剂通过抑制SGLT2,从而减少肾脏对葡萄糖的重吸收,增加尿糖排出,降低血糖。近期FDA更新SGLT2抑制剂标签,强调该药物酮症酸中毒和严重的尿路感染风险,这两种疾病均会导致住院治疗。2015年5月,FD

北京宣武医院鉴定两例国内首次发现菌种

近日,首都医科大学宣武医院检验科细菌室应用分子生物学技术和质谱技术,鉴定出两例国内首次发现的菌种。 一例是在血流感染(败血症和菌血症)患者血培养中分离出的Rothia aeria。该菌2004年从俄罗斯空间站的水和空气中被首次分离和鉴定,并由此命名,迄今为止很少引起人类感染,全球共6例报道,此例在国内为首例报道。另一例是在尿路感染患者尿液中,分离鉴定出Candida niva

可用于快速检测尿路感染的新仪器

德国和爱尔兰的一组科学家近日结合微流体技术和光学诊断技术共同研发出了一种可快速检测出尿路感染--一种诱发败血症的病因--的致病菌群的新型仪器,该仪器极大地缩短了检测尿路感染所需的时间,从原先的24小时缩短到70分钟。2015年8月11日华盛顿—尿路感染能够从一种令人痛苦的病症很快发展为威胁生命的紧急情况。 如果缺乏及时的治疗,有可能引发败血症--一种免疫系统在抵抗外界感染时不经意触发地全身性炎症,

雌激素有助抵御尿路感染

一项新研究称,在绝经后妇女中,雌激素可帮助保护其尿路免受感染。这些发现有助解释为什么雌激素补充剂可在绝经后妇女中抵御感染复发。 有多达60%的妇女至少会发生一次尿路感染,有25%的妇女有过反复的尿路感染。 Petra Lthje及其同事发现,雌激素可增加身体自制的被称作抗菌肽的抗生素的产生。研究人员给一组绝经后妇女为期2周的雌激素补充剂,并进行了分析。他们发现,雌激素会作用于基因表达,以帮助激